Protease Activated Receptor-1 and Brain Edema Formation in Glioma Models.

Qing Xie,Guohua Xi,Ye Gong,Richard Keep,Karin Muraszko,Ya Hua

DOI: https://doi.org/10.1007/978-3-7091-1434-6_35

2013-01-01

Abstract:Objective: Our previous studies showed that thrombin contributes to brain edema in gliomas. The present study investigated the role of a thrombin receptor, protease activated receptor-1 (PAR-1), in edema formation in glioma models.

What problem does this paper attempt to address?

[Roles of Protease-Activated Receptor-1 in Thrombin-Induced Brain Injury and Neurogenesis in Rats].

Feifei Liu,Fuyi Liu,Lin Wang,Hua Hu

DOI: https://doi.org/10.3785/j.issn.1008-9292.2013.03.006

2013-01-01

Abstract:OBJECTIVE To investigate the roles of protease-activated receptors (PARs) in thrombin-induced brain injury and neurogenesis in rats. METHODS Ninety male SD rats were randomly assigned to receive intra-hippocampus injection of NS, thrombin or specific agonists of 3 protease-activated receptors (PAR-1, PAR-3 and PAR-4), respectively. At 1,3 and 7 d after injection, the area of the hippocampus was determined with HE staining, the density and morphology of astrocyte were detected with GFAP staining, degenerated neurons were detected with Fluoro-Jade C staining, and the neurogenesis was examined with DCX staining. RESULTS Compared to NS injection, the area of the hippocampus significantly increased at 1-3 d and decreased at 7 d after the injection of thrombin and PAR-1 agonist (P<0.05). In addition, injection of thrombin and PAR-1 agonist significantly increased the density of astrocyte and Fluoro-Jade C positive cells at 1-7 d after injection (P<0.05), and significantly increased the density of DCX positive cells at 3-7 d after injection(P<0.05). The injection of PAR-3 agonist and PAR-4 agonist had no affect on the area of the hippocampus, the density of astrocyte, Fluoro-Jade C positive cells and DCX positive cells. CONCLUSION The activation of protease-activated receptor-1 may be related to the thrombin-induced brain injury and neurogenesis in rat hippocampus.
Thrombin Disrupts Vascular Endothelial-Cadherin and Leads to Hydrocephalus Via Protease-Activated Receptors-1 Pathway.

Xiao-Di Hao,Chen-Sheng Le,Hong-Mei Zhang,De-Sheng Shang,Lu-Sha Tong,Feng Gao

DOI: https://doi.org/10.1111/cns.13129

2019-01-01

CNS Neuroscience & Therapeutics

Abstract:AIMS:Previous studies indicated that intraventricular injection of thrombin would induce hydrocephalus. But how thrombin works in this process remains unclear. Since cadherin plays a critical role in hydrocephalus, we aimed to explore the mechanisms of how thrombin acted on choroid plexus vascular endothelium and how thrombin interacted with vascular endothelial-cadherin (VE-cadherin) during hydrocephalus.METHODS:There were two parts in this study. Firstly, rats received an injection of saline or thrombin into the right lateral ventricle. Magnetic resonance imaging was applied to measure the lateral ventricle volumes. Albumin leakage and Evans blue content were assessed to test the blood-brain barrier function. Immunofluorescence and Western blot were applied to detect the location and the expression of VE-cadherin. Secondly, we observed the roles of protease-activated receptors-1 (PAR1) inhibitor (SCH79797), Src inhibitor (PP2), p21-activated kinase-1 (PAK1) inhibitor (IPA3) in the thrombin-induced hydrocephalus, and their effects on the regulation of VE-cadherin.RESULTS:Our study demonstrated that intraventricular injection of thrombin caused significant downregulation of VE-cadherin in choroid plexus and dilation of ventricles. In addition, the inhibition of PAR1/p-Src/p-PAK1 pathway reversed the decrease of VE-cadherin and attenuated thrombin-induced hydrocephalus.CONCLUSIONS:Our results suggested that the thrombin-induced hydrocephalus was associated with the inhibition of VE-cadherin via the PAR1/p-Src/p-PAK1 pathway.
Role of Protease-Activated Receptor-1 in Glioma Growth.

Qing Xie,Xuhui Bao,Zhan Hong Chen,Ying Xu,Richard F Keep,Karin M Muraszko,Guohua Xi,Ya Hua

DOI: https://doi.org/10.1007/978-3-319-18497-5_61

2016-01-01

Abstract:Activation of a thrombin receptor, protease-activated receptor-1 (PAR-1), induces angiogenesis, cell proliferation, and invasion in tumors. The present study examined the effect of host PAR-1 gene deletion on glioma growth in a mouse model. F98 glioma cells were implanted into the right caudate of either wild type (WT) or PAR-1 knockout (KO) mice. Mice underwent magnetic resonance imaging (MRI) and the brains were used for measurements of brain water content and tumor mass. Levels of hypoxia-inducible factor-1 alpha (HIF-1α) and vascular endothelial growth factor (VEGF) were also measured by ELISA (enzyme-linked immunosorbent assay). We found brain water content in the ipsilateral hemisphere and the tumor mass were significantly lower in PAR-1 KO than WT mice at day 12 after implantation of F98 cells (p < 0.05). HIF-1α protein levels in the ipsilateral hemisphere were higher in the WT mice (373 ± 25 pg/g brain tissue vs 333 ± 35 pg/g brain tissue in PAR-1 KO mice, p < 0.05) 7 days after F98 cell implantation. VEGF protein levels were also higher in the ipsilateral hemisphere of WT mice (219 ± 21 vs 166 ± 22 pg/g brain tissue in PAR-1 KO mice, p < 0.01). In conclusion, PAR-1 has a role in glioma growth and could be a new therapeutic target for gliomas.
Role of protease activated receptor-1 in thrombin preconditioning against thrombin-induced brain injury in mice

Xuhui Bao,Fenghui Ye,Shu Wan,Ya Hua,Richard F. Keep,Hugh J. L. Garton,Guohua Xi

2019-01-01

Abstract:While high doses of thrombin can cause brain injury, pretreatment with a low dose of thrombin (thrombin preconditioning, TPC) protects neurons and astrocytes in culture from hypoglycemic and ischemic cell death in vitro and attenuates ischemic brain injury in vivo. This study investigated the role of protease activated receptor-1 (PAR-1), a thrombin receptor, in TPC. Wild type (WT) or PAR-1 knock-out (KO) female mice brains were respectively preconditioned with 0.1 U thrombin or saline by direct injection into the right basal ganglia. Seventy-two hours later, mice received a second injection of a large injurious dose (0.5 U) of thrombin. Brain water and sodium content, blood-brain barrier disruption, neuronal death, DNA injury, and behavioral deficits were evaluated on day 1. A subgroup of mice was euthanized 72 hours after TPC to examine the expression of heat shock protein (HSP) 25, HSP 32 and ceruloplasmin by Western blotting. This study found that TPC markedly attenuated brain edema (water content (%): 79.25 ± 0.51 in the WT TPC group vs. 80.30 ± 0 .18 in the WT saline group, n = 6 each group, p < 0.01), bloodbrain barrier disruption, neuronal death, DNA injury, and behavioral deficits (corner turn test scores (%): 47 ± 18 in the WT TPC group, n = 7 vs. 85 ± 24 in the WT saline group, n = 6, p < 0.01) that followed injection of a large dose of thrombin in WT mice without TPC. This effect of TPC was absent in PAR-1 KO mice. In addition, TPC upregulated brain HSP25, HSP32, and ceruloplasmin in WT mice but not PAR-1 KO mice (p < 0.01). In conclusion, PAR-1 plays a crucial role in the protective effects of TPC in female mice possibly via upregulation of heat shock proteins and ceruloplasmin.
Proteinase-Activated Receptor 1 Expression in Human Leukemia Hl-60 Cells and Its Significance.

Wan-Zhuo Xie,Mao-Fang Lin,He Huang,Zhen Cai

DOI: https://doi.org/10.1182/blood.v108.11.4484.4484

IF: 20.3

2006-01-01

Blood

Abstract:The coagulation system is regularly activated in patients with acute leukemia, especially with acute promyelocytic leukemia. Up to 30% of these patients suffer from thromboembolic complications. Obviously, activation of thrombin occurs in the natural course of cancer. During tumor progression, many patients develop coagulation disorders; treatment is complicated by increased resistance of tumor cells to chemotherapy. Thrombin-mediated activation of cellular receptor(s), such as proteinase-activated receptor-1(PAR-1), plays an important role in tumor growth, local progression, and distant metastasis. Our hypothesis is, that leukemia cells that express PAR-1 have a survival benefit if they are activated by thrombin.We harvested HL-60 cells in vitro. We detected PAR-1 expression using reverse transcription-polymerase chain reaction (RT-PCR) and fluorescence activated cell sorting (FACS) scan.We found that HL-60 cells expressed PAR-1 receptor. Furthermore,we employed a series of different concentrations of thrombin into the HL-60 cell culture system.With certain interval of low level of thrombin, HL-60 cell growth was enhanced,in contrast, we found that HL-60 cell apoptosis was observed under higher concentration of thrombin.In summary, we found that human leukemia HL-60 cell exhibits a positive PAR-1 expression. Also, thrombin could influence the growth of HL-60 mediated by PAR-1 possibly. Further experiments will show if these cell-biological mechanisms aggravate cellular proliferation/apoptosis in leukemia cells. Therapeutic consequences, such as therapeutic thrombin inhibition in addition to chemotherapy are discussed.
Thrombin-Induced Cerebral Hemorrhage: Role of Protease-Activated Receptor-1

Yingying Cheng,Guohua Xi,Hang Jin,Richard F. Keep,Jiachun Feng,Ya Hua

DOI: https://doi.org/10.1007/s12975-013-0288-8

2013-01-01

Translational Stroke Research

Abstract:Thrombin causes blood–brain barrier disruption, and this study examined whether thrombin can cause brain hemorrhage through protease-activated receptor-1 (PAR-1). Male wild type and PAR-1 knockout mice had an intracerebral injection of thrombin or saline. Mice then underwent serial T2 magnetic resonance imaging and were euthanized for brain hemoglobin, iron, and interleukin-1β measurements. Thrombin caused massive T2 lesions and brain hemorrhage in wild type mice. These effects were markedly reduced in PAR-1 knockout mice. Thrombin also increased brain interleukin-1β, and this was absent in PAR-1 knockout mice. In conclusion, thrombin increases interleukin-1β levels and induces intracerebral hemorrhage through PAR-1 activation.
Commutators of PAR-1 signaling in cancer cell invasion reveal an essential role of the Rho–Rho kinase axis and tumor microenvironment

Quang-Dé Nguyen,Olivier De Wever,Erik Bruyneel,An Hendrix,Wan-Zhuo Xie,Alain Lombet,Martin Leibl,Marc Mareel,Frank Gieseler,Marc Bracke,Christian Gespach

DOI: https://doi.org/10.1038/sj.onc.1208990

IF: 8.756

2005-01-01

Oncogene

Abstract:We recently reported that proteinase-activated receptors type I (PAR-1) are coupled to both negative and positive invasion pathways in colonic and kidney cancer cells cultured on collagen type I gels. Here, we found that treatments with the cell-permeant analog 8-Br-cGMP and the soluble guanylate cyclase activator BAY41-2272, and Rho kinase (ROK) inhibition by Y27632 or a dominant negative form of ROK lead to PAR-1-mediated invasion through differential Rac1 and Cdc42 signaling. Hypoxia or the counteradhesive matricellular protein SPARC/BM-40 (SPARC: secreted protein acidic rich in cysteine) overexpressed during cancer progression also commutated PAR-1 to cellular invasion through the cGMP/protein kinase G (PKG) cascade, RhoA inactivation, and Rac1-dependent or -independent signaling. Cultured primary cancer cells isolated from peritoneal and pleural effusions from patients with colon cancer or other malignant tumors harbored PAR-1, as shown by RT–PCR and FACS analyses. These malignant effusions also contained high levels of activated thrombin and fibrin, and induced a proinvasive response in HCT8/S11 human colorectal cancer cells. Our data underline the essential role of the tumor microenvironment and of several commutators targeting cGMP/PKG signaling and the RhoA–ROK axis in the control of PAR-1 proinvasive activity and metastatic potential of cancer cells in distant organs and peritoneal or pleural cavities. We also add new insights into the mechanisms linking the coagulation mediators thrombin and PAR-1 in the context of blood coagulation disorders and venous thrombosis often observed in cancer patients, as described in 1865 by Armand Trousseau.
Tissue plasminogen activator expression and barrier properties of human brain microvascular endothelial cells.

Fan Yang,Shuo Liu,Shur-Jen Wang,Chuanhui Yu,Annlia Paganini-Hill,Mark J Fisher

DOI: https://doi.org/10.1159/000335785

2011-01-01

Cellular Physiology and Biochemistry

Abstract:Background: Tissue plasminogen activator (tPA) regulates fibrinolysis and is routinely used as ischemic stroke pharmacotherapy. We hypothesized that brain microvascular tPA expression and barrier properties of endothelial cells are substantially related. Methods: Human brain microvascular endothelial cells were incubated with two agents known to modify cAMP pathways: forskolin and rolipram. We analyzed development of endothelial barrier properties, i.e., trans-endothelial electrical resistance (TEER), permeability of endothelial cell monolayer, expression of influx transporter glut-1 and endothelial tight junction molecules occludin and claudin-5, tPA antigen release, and levels of endothelial tPA mRNA. Results: Forskolin plus rolipram-treated endothelial cells showed increased TEER compared to controls (174 +/- 20% of control at day six, p<0.01), while permeability to albumin and 70kDa dextran was reduced (21 +/- 6.8% of control and 3.8 +/- 0.3% of control, respectively, p<0.001). In addition, occludin and claudin-5 protein were up-regulated, occludin mRNA was increased to 206 +/- 60% of control (p<0.05), glut-1 mRNA was increased to 196 +/- 8% of control (p<0.05), levels of tPA protein were reduced to 35 +/- 7.0% of control (p<0.001) after six days, and tPA mRNA was reduced to 32 +/- 7.7% of control (p<0.01). TPA and occludin mRNA levels were inversely associated (r=-0.68, p<0.05). Conclusions: In this in vitro model, barrier properties were strongly linked (by inverse association) with tPA expression of brain microvascular endothelial cells. Copyright (C) 2011 S. Karger AG, Basel
Abstract TP292: Thrombin-induced Cerebral Hemorrhage: Role of Protease-activated Receptor-1

Yingying Cheng,Guohua Xi,Richard F Keep,Jiachun Feng,Ya Hua

DOI: https://doi.org/10.1161/str.44.suppl_1.atp292

IF: 10.17

2013-01-01

Stroke

Abstract:Background and Purpose: Thrombin causes blood-brain barrier disruption and this study examined whether thrombin can cause brain hemorrhage through protease-activated receptor-1 (PAR-1). Methods: Male wild type and PAR-1 knockout mice had an intracerebral injection of thrombin or saline. Mice then underwent serial T2 magnetic resonance imaging and were euthanized for brain hemoglobin, iron and interleukin-1β measurements. Results: Mortality after intracerebral thrombin injection was not significantly different in WT (11%) and PAR-1 KO mice (9%). Thrombin but not saline resulted in massive T2 lesions in WT mice. MRI studies showed that the T2 lesions induced by thrombin were smaller in PAR-1 KO mice compared to those in WT mice (p<0.05). An examination of brain sections after thrombin injection showed areas of hemorrhage in the ipsilateral hemisphere. This hemorrhage was examined using Perls’ staining for iron and by measuring brain hemoglobin. Perls’ staining showed that thrombin caused significant brain hemorrhage in WT mice and that hemorrhage peaked at day-3. Perls’ positive cells were less in PAR-1 KO mice (p<0.05). Brain hemoglobin content was measured at day-3 after thrombin injection to assess hemorrhage volume. Thrombin-induced marked hemoglobin accumulation in the ipsilateral hemisphere in WT-type mice and this was markedly reduced in PAR-1 KO mice (hemoglobin: 327±134 vs. 913±221 μg in the WT mice, p<0.01). The role of PAR-1 in brain IL-1β levels after thrombin stimulation was also examined. The time course of brain IL-1β levels following thrombin injection in WT mice was examined. Brain IL-1β levels peaked at 12 hours and returned to low levels after 24 hours. We then measured brain IL-1β levels in WT and PAR-1 KO mice and found that thrombin-induced upregulation of brain IL-1β was basically absent in PAR-1 KO mice (p<0.01). Conclusions: Thrombin increases interleukin-1β levels and induces intracerebral hemorrhage through PAR-1 activation.
Proteinase-activated Receptor-1 Antagonist Attenuates Brain Injury via Regulation of FGL2 and TLR4 after Intracerebral Hemorrhage in Mice

Xiaoying Yao,Yaying Song,Ze Wang,Shuwei Bai,Haojun Yu,Yishu Wang,Yangtai Guan

DOI: https://doi.org/10.1016/j.neuroscience.2022.02.012

IF: 3.708

2022-01-01

Neuroscience

Abstract:•PAR1 antagonist protected against short-term brain injury after ICH.•Suppression of FGL2 or TLR4 ameliorated brain injury after ICH.•The role of PAR1 antagonist in ICH-induced brain injury was mediated by FGL2 or TLR4.
The Role of Protease-Activated Receptor 1 in Thrombin-Mediated Lung Cancer Cell Function Responses

HE Zi-Yang,ZHU Ling-Yun,MAO De-Kui,WANG Xiu-Dong,YU Ai-Ping,WU Zu-Ze

DOI: https://doi.org/10.3969/j.issn.1009-0002.2012.04.007

2012-01-01

Abstract:Objective: To evaluate the role of protease-activated receptor 1(PAR1) in thrombin-mediated lung cancer cell function responses.Methods: The recombinant vector pSilence-shPAR1 and pIRES-EGFP-PAR1 plas mids were transferred into lung cancer cell PLA-801D and PLA-801C,respectively.Reverse transcription PCR and real-time fluorescent quantitative PCR were used to detect the level of PAR1 mRNA.Transwell migration chamber was used to evaluate the ability of migration.The ability of the cell adhesion to extracellular matrix was evaluated with cell adhesion assay.The proliferation of the cell was measured with colony formation assay.The ability of collagen remodeling by lung cancer cells was measured with collagen contraction assay.Results: The overexpression of PAR1 in PLA-801C cells(PLA-801C-pIRES-EGFP-PAR1) significantly enhanced thrombin-medi ated cell migration,adhesion,proliferation and collagen contraction(P<0.05,P<0.001).The interference of PAR1 in PLA-801D cells(PLA-801D-pSilence-shPAR) markedly attenuated the thrombin-mediated cell function(P<0.05,P<0.001).Conclusion: PAR1 play an important role in thrombin-mediated lung cancer cell function responses,in dicating that PAR1 can be seen as an attractive therapeutic target in lung cancer therapy.
Protease-Activated Receptors in Cancer: A Systematic Review

Na Han,Ketao Jin,Kuifeng He,Jiang Cao,Lisong Teng

DOI: https://doi.org/10.3892/ol.2011.291

2011-01-01

Oncology Letters

Abstract:The traditional view of the role of proteases in tumor growth, progression and metastasis has significantly changed. Apart from their contribution to cancer progression, it is evident that a subclass of proteases, such as thrombin, serves as signal molecules controlling cell functions through the protease-activated receptors (PARs). Among the four types of PAR (PAR 1-4; cloned and named in order of their discovery), PAR1, PAR3 and PAR4 are activated by thrombin, unlike PAR2, which is activated by trypsin-like serine proteases. Thrombin has been proven to be a significant factor in both the behavior of cancer in its involvement in hemostasis and blood coagulation. Thrombin is a key supporter of various cellular effects relevant to tumor growth and metastasis, as well as a potent activator of angiogenesis, which is essential for the growth and development of all solid tumor types. This review presents an overview of the role of PAR-mediated thrombin in angiogenesis and cancer, focusing on the ability of PAR1- and PAR4-mediated thrombin to affect tumorigenesis and angiogenesis.
Thrombin Enhanced Matrix Metalloproteinase-9 Expression and Migration of SK-N-SH Cells via PAR-1, c-Src, PYK2, EGFR, Erk1/2 and AP-1

Chien-Chung Yang,Li-Der Hsiao,Chuen-Mao Yang,Chih-Chung Lin

DOI: https://doi.org/10.1007/s12035-016-9916-0

Abstract:Neuroinflammation is a hallmark of neurodegenerative disorders in the central nerve system (CNS). Thrombin has been known as one of the factors in pathological processes including migration, blood-brain barrier breakdown, brain edema formation, neuroinflammation, and neuronal death. Thrombin has been shown to be a regulator of matrix metalloproteinase (MMPs) expression leading to cell migration. Among MMPs, the elevated expression of MMP-9 has been observed in patients with brain diseases, which may contribute to the pathology of neuroinflammatory and neurodegenerative diseases. However, the mechanisms underlying thrombin-induced MMP-9 expression in SK-N-SH cells were not completely understood. Here, we used gelatin zymography, Western blot, real-time PCR, promoter activity assay, and cell migration assay to demonstrate that thrombin induced the expression of pro-form MMP-9 protein and messenger RNA (mRNA), and promoter activity in SK-N-SH cells, which were attenuated by pretreatment with the pharmacological inhibitor of protease-activated receptor-1 (PAR-1, SCH79797), Gi-coupled receptor (GPA2), c-Src (PP1), Pyk2 (PF431396), EGFR (AG1478), PI3K (LY294002), Akt (SH-5), MEK1/2 (U0126), or AP-1 (TanshinoneIIA) and transfection with small interfering RNA (siRNA) of PAR-1, Gi, c-Src, Pyk2, EGFR, Akt, p44, p42, or c-Jun. Moreover, thrombin-stimulated c-Src, Pyk2, EGFR, Akt, p42/p44 MAPK, or c-Jun phosphorylation was attenuated by their respective inhibitor of PP1, PF431396, AG1478, SH-5, U0126, or TanshinoneIIA. Finally, pretreatment with these inhibitors also blocked thrombin-induced SK-N-SH cell migration. Our results concluded that thrombin binding to PAR-1 receptor activated Gi-protein/c-Src/Pyk2/EGFR/PI3K/Akt/p42/p44 MAPK cascade, which in turn elicited AP-1 activation and ultimately evoked MMP-9 expression and cell migration in SK-N-SH cells.
Thrombin-receptor activation and thrombin-induced brain tolerance.

Yajun Jiang,Jimin Wu,Ya Hua,Richard F Keep,Jianming Xiang,Julian T Hoff,Guohua Xi

DOI: https://doi.org/10.1097/00004647-200204000-00004

2002-01-01

Abstract:The authors previously found that pretreatment with a low dose of thrombin attenuates the brain edema induced by a large dose of thrombin or an intracerebral hemorrhage, and reduces infarct volume after focal cerebral ischemia (i.e., thrombin preconditioning). This study investigated whether thrombin preconditioning is caused by activation of the thrombin receptor, also called protease-activated receptor. In the in vivo studies, thrombin-induced brain tolerance was eliminated by RPPGF (Arg-Pro-Pro-Gly-Phe), a thrombin-receptor antagonist. Pretreatment with a thrombin-receptor agonist reduced the amount of edema induced by a large dose of thrombin infused into the ipsilateral basal ganglia 7 days later (81.3 +/- 0.7% vs. 82.6 +/- 0.8% in the control, P < 0.05). In the in vitro study, low doses of thrombin (1 or 2 U/mL) did not induce cell death. However, doses greater than 5 U/mL resulted in dose-dependent lactate dehydrogenase release (P < 0.01). Thrombin and thrombin receptor-activating peptide preconditioning reduced lactate dehydrogenase release induced by a high dose of thrombin (10 and 20 U/mL), whereas RPPGF blocked the effect of thrombin preconditioning in vitro. Western blots indicated that p44/42 mitogen-activated protein kinases were activated after thrombin preconditioning. Finally, inhibition of p44/42 mitogen-activated protein kinases activation by PD98059 abolished the thrombin-preconditioning effect. Results indicate that thrombin-induced brain tolerance is in part achieved through activation of the thrombin receptor. Activation of the thrombin receptor in the brain may be neuroprotective. The protective effect of thrombin preconditioning is achieved through the p44/42 mitogen-activated protein kinase signal-transduction pathway.
SUR1-TRPM4 channel activation and phasic secretion of MMP-9 induced by tPA in brain endothelial cells

Volodymyr Gerzanich,Min Seong Kwon,Seung Kyoon Woo,Alexander Ivanov,J Marc Simard

DOI: https://doi.org/10.1371/journal.pone.0195526

IF: 3.7

2018-04-04

PLoS ONE

Abstract:Background: Hemorrhagic transformation is a major complication of ischemic stroke, is linked to matrix metalloproteinase-9 (MMP-9), and is exacerbated by tissue plasminogen activator (tPA). Cerebral ischemia/reperfusion is characterized by SUR1-TRPM4 (sulfonylurea receptor 1-transient receptor potential melastatin 4) channel upregulation in microvascular endothelium. In humans and rodents with cerebral ischemia/reperfusion (I/R), the SUR1 antagonist, glibenclamide, reduces hemorrhagic transformation and plasma MMP-9, but the mechanism is unknown. We hypothesized that tPA induces protease activated receptor 1 (PAR1)-mediated, Ca2+-dependent phasic secretion of MMP-9 from activated brain endothelium, and that SUR1-TRPM4 is required for this process. Methods: Cerebral I/R, of 2 and 4 hours duration, respectively, was obtained using conventional middle cerebral artery occlusion. Immunolabeling was used to quantify p65 nuclear translocation. Murine and human brain endothelial cells (BEC) were studied in vitro, without and with NF-κB activation, using immunoblot, zymography and ELISA, patch clamp electrophysiology, and calcium imaging. Genetic and pharmacological manipulations were used to identify signaling pathways. Results: Cerebral I/R caused prominent nuclear translocation of p65 in microvascular endothelium. NF-κB-activation of BEC caused de novo expression of SUR1-TRPM4 channels. In NF-κB-activated BEC: (i) tPA caused opening of SUR1-TRPM4 channels in a plasmin-, PAR1-, TRPC3- and Ca2+-dependent manner; (ii) tPA caused PAR1-dependent secretion of MMP-9; (iii) tonic secretion of MMP-9 by activated BEC was not influenced by SUR1 inhibition; (iv) phasic secretion of MMP-9 induced by tPA or the PAR1-agonist, TFLLR, required functional SUR1-TRPM4 channels, with inhibition of SUR1 decreasing tPA-induced MMP-9 secretion. Conclusions: tPA induces PAR1-mediated, SUR1-TRPM4-dependent, phasic secretion of MMP-9 from activated brain endothelium.
Protease-activated Receptor-1 (PAR-1): a Promising Molecular Target for Cancer

Xuan Liu,Jiahui Yu,Shangjin Song,Xiaoqiang Yue,Qi Li

DOI: https://doi.org/10.18632/oncotarget.21015

2017-01-01

Oncotarget

Abstract:PAR-1 is expressed not only in epithelium, neurons, astrocytes, immune cells, but also in cancer-associated fibroblasts, ECs (epithelial cells), myocytes of blood vessels, mast cells, and macrophages in tumor microenvironment, whereas PAR-1 stimulates macrophages to synthesize and secrete thrombin as well as other growth factors, resulting in enhanced cell proliferation, tumor growth and metastasis. Therefore, considerable effort has been devoted to the development of inhibitors targeting PAR-1. Here, we provide a comprehensive review of PAR-1's role in cancer invasiveness and dissemination, as well as potential therapeutic strategies targeting PAR-1 signaling.
The Role of Thrombin in Brain Injury After Hemorrhagic and Ischemic Stroke

Fenghui Ye,Hugh J. L. Garton,Ya Hua,Richard F. Keep,Guohua Xi

DOI: https://doi.org/10.1007/s12975-020-00855-4

2020-09-29

Translational Stroke Research

Abstract:Thrombin is increased in the brain after hemorrhagic and ischemic stroke primarily due to the prothrombin entry from blood either with a hemorrhage or following blood-brain barrier disruption. Increasing evidence indicates that thrombin and its receptors (protease-activated receptors (PARs)) play a major role in brain pathology following ischemic and hemorrhagic stroke (including intracerebral, intraventricular, and subarachnoid hemorrhage). Thrombin and PARs affect brain injury via multiple mechanisms that can be detrimental or protective. The cleavage of prothrombin into thrombin is the key step of hemostasis and thrombosis which takes place in every stroke and subsequent brain injury. The extravascular effects and direct cellular interactions of thrombin are mediated by PARs (PAR-1, PAR-3, and PAR-4) and their downstream signaling in multiple brain cell types. Such effects include inducing blood-brain-barrier disruption, brain edema, neuroinflammation, and neuronal death, although low thrombin concentrations can promote cell survival. Also, thrombin directly links the coagulation system to the immune system by activating interleukin-1α. Such effects of thrombin can result in both short-term brain injury and long-term functional deficits, making extravascular thrombin an understudied therapeutic target for stroke. This review examines the role of thrombin and PARs in brain injury following hemorrhagic and ischemic stroke and the potential treatment strategies which are complicated by their role in both hemostasis and brain.

neurosciences,clinical neurology
Microglia Activation and Polarization After Intracerebral Hemorrhage in Mice: the Role of Protease-Activated Receptor-1

Shu Wan,Yingying Cheng,Hang Jin,Dewei Guo,Ya Hua,Richard F Keep,Guohua Xi

DOI: https://doi.org/10.1007/s12975-016-0472-8

Abstract:Polarized microglia play a dual (beneficial/detrimental) role in neurological diseases. However, the status and the factors that modulate microglia polarization in intracerebral hemorrhage (ICH) remain unclear. In the present study, we investigated the role of protease-activated receptor-1 (PAR-1, a thrombin receptor) in ICH-induced microglia polarization in mice. Male wild-type (WT) and PAR-1 knockout (PAR-1 KO) mice received an infusion of 30-μL autologous blood or saline into the right basal ganglia. Mice were euthanized at different time points and the brains were used for Western blotting and immunohistochemistry. Some mice had magnetic resonance imaging. We found that ICH induced microglia activation and polarization. M1 phenotypic markers were markedly increased and reached a peak as early as 4 h, remained high at 3 days and decreased 7 days after ICH. M2 phenotypic markers were upregulated later than M1 markers reaching a peak at day 1 and declining by day 7 after ICH. PAR-1 was upregulated after ICH and expressed in the neurons and microglia. ICH induced less brain swelling and neuronal death in PAR-1 KO mice, and this was associated with less M1 polarization and reduced proinflammatory cytokine levels in the brain. In conclusion, these results suggest that polarized microglia occur dynamically after ICH and that PAR-1 plays a role in the microglia activation and polarization.
Protease Activated Receptor 1 (Par1) Enhances Src-Mediated Tyrosine Phosphorylation Of Nmda Receptor In Intracerebral Hemorrhage (Ich)

Zhen-Zhen Duan,Feng Zhang,Feng-Ying Li,Yi-Fei Luan,Peng Guo,Yi-Hang Li,Yong Liu,Su-Hua Qi

DOI: https://doi.org/10.1038/srep29246

IF: 4.6

2016-01-01

Scientific Reports

Abstract:It has been demonstrated that Src could modulate NMDA receptor, and PAR1 could also affect NMDAR signaling. However, whether PAR1 could regulate NMDAR through Src under ICH has not yet been investigated. In this study, we demonstrated the role of Src-PSD95-GluN2A signaling cascades in rat ICH model and in vitro thrombin challenged model. Using the PAR1 agonist SFLLR, antagonist RLLFS and Src inhibitor PP2, electrophysiological analysis showed that PAR1 regulated NMDA-induced whole-cell currents (I-NMDA) though Src in primary cultured neurons. Both in vivo and in vitro results showed the elevated phosphorylation of tyrosine in Src and GluN2A and enhanced interaction of the Src-PSD95-GluN2A under model conditions. Treatment with the PAR1 antagonist RLLFS, AS-PSD95 (Antisense oligonucleotide against PSD95) and Src inhibitor PP2 inhibited the interaction among Src-PSD95-GluN2A, and p-Src, p-GluN2A. Co-application of SFLLR and AS-PSD95, PP2, or MK801 (NMDAR inhibitor) abolished the effect of SF. In conclusion, our results demonstrated that activated thrombin receptor PAR1 induced Src activation, enhanced the interaction among Src-PSD95-GluN2A signaling modules, and up-regulated GluN2A phosphorylation after ICH injury. Elucidation of such signaling cascades would possibly provide novel targets for ICH treatment.
Par-1 Antagonist Sch79797 Ameliorates Apoptosis Following Surgical Brain Injury Through Inhibition of Ask1-Jnk in Rats

Anatol Manaenko,Xuejun Sun,Cherine H. Kim,Junhao Yan,Qingyi Ma,John H. Zhang

DOI: https://doi.org/10.1016/j.nbd.2012.09.004

IF: 7.046

2013-01-01

Neurobiology of Disease

Abstract:Neurosurgical procedures inevitably produce intraoperative hemorrhage. The subsequent entry of blood into the brain parenchyma results in the release of large amounts of thrombin, a known contributor to perihematomal edema formation and apoptosis after brain injury. The present study seeks to test 1) the effect of surgically induced brain injury (SBI) on thrombin activity, expression of thrombin's receptor PAR-1, and PAR-1 mediated apoptosis; 2) the effect of thrombin inhibition by argatroban and PAR-1 inhibition by SCH79797 on the development of secondary brain injury in the SBI model on rats.A total of 88 Sprague–Dawley male rats were randomly divided into sham, vehicle-, argatroban-, or SCH79797-treated groups. SBI involved partial resection of the right frontal lobe under inhalation isoflurane anesthesia. Sham-operated animals received only craniotomy. Thrombin activity, brain water content, and neurological deficits were measured at 24 h following SBI. Involvement of the Ask1/JNK pathway in PAR-1-induced post-SBI apoptosis was characterized by using Ask1 or JNK inhibitors.We observed that SBI increased thrombin activity, yet failed to demonstrate any effect on PAR-1 expression. Argatroban and SCH79797 reduced SBI-induced brain edema and neurological deficits in a dose-dependent manner. SBI-induced apoptosis seemed mediated by the PAR-1/Ask1/JNK pathways. Administration of SCH79797 ameliorated the apoptosis following SBI.Our findings indicate that PAR-1 antagonist protects against secondary brain injury after SBI by decreasing both brain edema and apoptosis by inactivating PAR-1/Ask1/JNK pathway. The anti-apoptotic effect of PAR-1 antagonists may provide a promising path for therapy following SBI.

Protease Activated Receptor-1 and Brain Edema Formation in Glioma Models.

[Roles of Protease-Activated Receptor-1 in Thrombin-Induced Brain Injury and Neurogenesis in Rats].

Thrombin Disrupts Vascular Endothelial-Cadherin and Leads to Hydrocephalus Via Protease-Activated Receptors-1 Pathway.

Role of Protease-Activated Receptor-1 in Glioma Growth.

Role of protease activated receptor-1 in thrombin preconditioning against thrombin-induced brain injury in mice

Proteinase-Activated Receptor 1 Expression in Human Leukemia Hl-60 Cells and Its Significance.

Thrombin-Induced Cerebral Hemorrhage: Role of Protease-Activated Receptor-1

Commutators of PAR-1 signaling in cancer cell invasion reveal an essential role of the Rho–Rho kinase axis and tumor microenvironment

Tissue plasminogen activator expression and barrier properties of human brain microvascular endothelial cells.

Abstract TP292: Thrombin-induced Cerebral Hemorrhage: Role of Protease-activated Receptor-1

Proteinase-activated Receptor-1 Antagonist Attenuates Brain Injury via Regulation of FGL2 and TLR4 after Intracerebral Hemorrhage in Mice

The Role of Protease-Activated Receptor 1 in Thrombin-Mediated Lung Cancer Cell Function Responses

Protease-Activated Receptors in Cancer: A Systematic Review

Thrombin Enhanced Matrix Metalloproteinase-9 Expression and Migration of SK-N-SH Cells via PAR-1, c-Src, PYK2, EGFR, Erk1/2 and AP-1

Thrombin-receptor activation and thrombin-induced brain tolerance.

SUR1-TRPM4 channel activation and phasic secretion of MMP-9 induced by tPA in brain endothelial cells

Protease-activated Receptor-1 (PAR-1): a Promising Molecular Target for Cancer

The Role of Thrombin in Brain Injury After Hemorrhagic and Ischemic Stroke

Microglia Activation and Polarization After Intracerebral Hemorrhage in Mice: the Role of Protease-Activated Receptor-1

Protease Activated Receptor 1 (Par1) Enhances Src-Mediated Tyrosine Phosphorylation Of Nmda Receptor In Intracerebral Hemorrhage (Ich)

Par-1 Antagonist Sch79797 Ameliorates Apoptosis Following Surgical Brain Injury Through Inhibition of Ask1-Jnk in Rats